2-(3-Methyl-1-phenyl-1H-pyrazol-4-yl)-3-phenylthiazolidin-4-ones as Potent Antioxidant and Antidiabetic Agent

SANDIP SEN^{1,*}, BIPLAB DE² and T.S. EASWARI¹

¹IIMT College of Medical Sciences, O. Pocket, Ganga Nagar, Meerut-250 001, India

²Regional Institute of Pharmaceutical Science and Technology, Abhoynagar, Agartala-799 006, India

*Corresponding author: E-mail: sandipsen2010@gmail.com

Received: 7 January 2014;

Accepted: 22 February 2014;

Published online: 16 September 2014;

AJC-15974

A series of 2-(3-methyl-1-phenyl-1H-pyrazol-4-yl)-3-phenylthiazolidin-4-ones (**7a-7j**) were synthesized by intramolecular cyclization of imines (**6a-6j**) with thioglycolic acid in the presence of acid catalyst. The Schiff bases were obtained upon reaction between electrophilic carbon atom of 3-methyl-1-phenyl-1H-pyrazole-4-carbaldehyde (**4**) and nucleophilic nitrogen atom of substituted aromatic amines. *in vitro* Antioxidant activity was determined by DPPH radical scavenging assay method using ascorbic acid as standard. The antidiabetic activity was carried out by streptozotocin induced diabetic method using rosiglitazone as standard drug on wistar rats. From the study it was found that 3-(4-chlorophenyl)-2-(3-methyl-1-phenyl-1H-pyrazol-4-yl)thiazolidin-4-one (**7a**), 3-(4-bromophenyl)-2-(3-methyl-1-phenyl-1H-pyrazol-4-yl)thiazolidin-4-one (**7b**), 3-(3,4-dichlorophenyl)-2-(3-methyl-1-phenyl-1H-pyrazol-4-yl)thiazolidin-4-one (**7d**), 3-(3,4-difluorophenyl)-2-(3-methyl-1-phenyl-1H-pyrazol-4-yl)thiazolidin-4-one (**7f**), 2-(3-methyl-1-phenyl-1H-pyrazol-4-yl)-3-(4-(trifluoromethyl)phenyl)thiazolidin-4-one (**7h**), 3-(4-methoxyphenyl)-2-(3-methyl-1-phenyl-1H-pyrazol-4-yl)thiazolidin-4-one (**7j**) shown more IC₅₀ compare to standard. Where as compound **7a**, **7b**, **7h**, **7j** show more significant antidiabetic effect against hyperglycemic rats compare to standard drugs at the dose of 5 mg/kg after 21 days of treatment.

Keywords: Pyrazole-4-carboxaldehydes, Thiazolidine-4-one, Antioxidant, Antidiabetic.

INTRODUCTION

Among the wide variety of heterocyclic compounds pyrazoles fused with different heterocycles known to contribute various pharmacological effects. Due to wide range of pharmacological activity there were significant amount of research activity directed towards this class. In particular, they were used as antitumor, antibacterial and antifungal, antiviral, anti-parasitic, antitubercular and insecticidal agents. Some of these compounds have also shown antiinflammatory, antidiabetic, anesthetic and analgesic properties¹. Another heterocyclic compound thiazolidine is a 5 membered saturated ring with a thio ether group at position 1 and an amino group at the position 3. It has fungicidal, local anesthetic, antiseizure, antitubercular, antibacterial, antiamoebic, antidiabetic and antiinflammatory activities^{2,3}. Thiazolidinones are derivatives of thiazolidine, which is a main pharmacophoric group responsible for antidiabetic activity. It acted by enhancing insulin sensitivity in both muscle and adipose tissue and to a lesser extent by inhibiting hepatic glucose production. These agents have a notable effect on improving insulin resistance, particularly when used in combination with other antidiabetic drugs, but have no effect on insulin secretion. As a class, the thiazolidinediones have

also been shown to alter lipid profiles in patients with type 2 diabetes. They also have shown a decrease in triglyceride levels, increase in total and LDL cholesterol levels⁴. In patients receiving insulin therapy, the addition of a thiazolidinedione has resulted in significant reductions in daily insulin requirements^{5,6}. The thiazolidine were dependent on the presence of insulin for activity; however, they do not affect insulin secretion. It was also found that patients with chronic pancreatitis had high risk of antioxidant deficiencies. Furthermore, this disease can lead to diabetes mellitus that could exacerbate the severity of oxidative stress. Oxidative stress and the resulting LDL oxidation considered major cause of atherosclerosis⁷.

EXPERIMENTAL

All the chemicals used for the synthesis were reagent grade and of Sigma Aldrich and Merck Laboratory. The solvents were purified by standard laboratory procedure and free from atmospheric oxygen. The melting points were determined by open capillary method and were not corrected. The IR spectra were recorded in KBr pellets on a Shimadzu 8201 PC FTIR spectrophotometer. Both ¹H and ¹³C NMR were recorded in DMSO-*d*₆ using Bruker 500 MHz-NMR spectrophotometers

using TMS as internal standard. The masses of the compound were analyzed by ESI-mass method using Thermo Finnigan mass spectrophotometer. Elemental analyses were recorded using Thermo Finnigan FLASH EA 1112 CHN analyzer. TLC was performed in precoated plastic sheet of silica gel g/UV-254 of 0.2 mm thickness.

Synthesis of 3-methyl-1-phenyl-1, 2-dihydropyrazol-5-one (3): 1 Mole of phenyl hydrazine was taken in 500 mL beaker. 1 Mole equivalent of ethyl acetoacetate was added and allowed to warm the mixture at 100 °C on water bath for 3 h. Cooling of the mixture at room temperature resulted solidification of crystal. Washing was taken place with ether and recrystallized from hot ethanol⁸. Yield: 93 %; m.p. 193-194 °C; ¹H NMR (DMSO-*d*₆, δ ppm): 7.18 (m, 2H, Ar-H), 6.71-6.69 (d, 1H, *J* = 10 Hz, Ar-H), 6.66-6.64 (d, 2H, *J* = 10 Hz, Ar-H), 5.18 (s, 1H, Ar-H of pyrazole), 2.15 (s, 1H, -NH- of pyrazole), 1.17 (s, 3H, -CH₃ of pyrazole).

Synthesis of 3-methyl-1-phenyl-1H-pyrazole-4-carbaldehyde (4): Taken 3 mole of 3-methyl-1-phenyl-1,2-dihydropyrazol-5-one (3) in round bottom flask and was added 3 mole of DMF and 1 mole of POCl₃. During addition of POCl₃ the temperature of reaction mixture was maintained 0-5 °C. After completion of addition reflux the mixture for 6 h. Added sodium hydroxide and was cool for overnight. After addition of crushed ice formation of precipitation was taken place. Recrystallized from hot ethanol⁹. Yield: 83 %; m.p. 146-147 °C; ¹H NMR (DMSO-*d*₆, δ ppm): 8.52 (s, 1H, -CHO), 7.82 (s, 1H, Ar-H); 7.31 (s, 6H, Ar-H); 2.79 (s, 3H, -CH₃ of pyrazole).

Synthesis of N-((3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene) benzenamine (6)¹⁰: 1 mmol equivalent of 3-methyl-1-phenyl-1H-pyrazole-4-carbaldehyde (4) was added in 50 mL of ethanol. Stirred the reaction mixture for 1 h under nitrogen atmosphere. Added 1 mmol of glacial acetic acid. After that added substituent aromatic amines in 1 mmol equivalent and refluxed for 1 h. Then added crushed ice, filter the precipitate. Dried at room temperature and recrystallized from hot ethanol¹⁰.

4-Chloro-N-((3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene)benzenamine (6a): Yield: 93 %; m.p. 85-86 °C; IR (KBr, $\nu_{\max}$, cm⁻¹): 2955.34 (-CH₃, str), 1450.14 (-CH₃, def), 1671.67 (C=N, str), 664.21 (C-Cl, str); ¹H NMR (DMSO-*d*₆, δ ppm): 13.7 (s, 1H, -NH), 7.52 (s, 1H, -N=CH-), 7.31 (s, 5H), 7.2-7.18 (d, 2H, *J* = 10 Hz, Ar-H), 7.15 (s, 1H, Ar-H), 6.8-6.78 (d, 2H, *J* = 10 Hz, Ar-H); ¹³C NMR (DMSO-*d*₆, δ ppm): 160.1, 147.1, 145.5, 141.4, 139.7, 132.8, 131.4, 130.2, 130.2, 129.4, 129.4, 126.3, 123.7, 123.7, 120.2, 105; ESI-Mass (*m/z*): 295.09 (M⁺). Anal. (%) calcd. (found) for C₁₇H₁₄N₃Cl: C-69.03 (68.89), H- 4.77 (4.37), N-14.21 (14.11).

4-Bromo-N-((3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene)benzenamine (6b): Yield: 92 %; m.p. 85-86 °C; IR (KBr, $\nu_{\max}$, cm⁻¹): 2956.52 (-CH₃, str), 1469.35 (-CH₃, def), 1624.73 (C=N, str), 621.93 (C-Br, str); ¹H NMR (DMSO-*d*₆, δ ppm): 13.7 (s, 1H, -NH), 7.53 (s, 1H, -N=CH-), 7.21 (s, 5H), 7.19-7.18 (d, 2H, *J* = 5 Hz, Ar-H), 7.15 (s, 1H, Ar-H), 6.8-6.78 (d, 2H, *J* = 10 Hz, Ar-H); ¹³C NMR (DMSO-*d*₆, δ ppm): 162.1, 147.5, 145.7, 141.4, 139.7, 132.8, 131.4, 130.7, 130.7, 129.4, 129.4, 126.3, 121.7, 121.7, 118.2, 105.7. ESI mass (*m/z*): 339.13 (M⁺); Anal. (%) calcd. (found) for C₁₇H₁₄N₃Br: C-60.02 (59.89), H- 4.15 (4), N-12.35 (12.27).

4-Nitro-N-((3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene)benzenamine (6c): Yield: 87 %; m.p. 95-97 °C; IR (KBr, $\nu_{\max}$, cm⁻¹): 2953.52 (-CH₃, str), 1685.73 (C=N, str), 1540.02 (C-NO₂, str), 1450.35 (-CH₃, def). ¹H NMR (DMSO-*d*₆, δ ppm): 12.9 (s, 1H, -NH), 7.43 (s, 1H, -N=CH-), 7.33 (s, 5H), 7.20-7.18 (d, 2H, *J* = 10 Hz, Ar-H), 7.15 (s, 1H, Ar-H), 6.8-6.78 (d, 2H, *J* = 10 Hz, Ar-H); ¹³C NMR (DMSO-*d*₆, δ ppm): 162.1, 147.5, 145.2, 143.4, 136.7, 133.8, 131.4, 130.7, 130.7, 129.4, 129.4, 126.3, 121.7, 121.7, 118.2, 105.7; ESI mass (*m/z*): 306.11 (M⁺). Anal. (%) calcd. (found) for C₁₇H₁₄N₄O₂: C-60.02 (59.89); H- 4.61 (4.41), N-18.21 (18.19).

3,4-Dichloro-N-((3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene)benzenamine (6d): Yield: 88 %; m.p. 83-84 °C; IR (KBr, $\nu_{\max}$, cm⁻¹): 2927.14 (-CH₃, str), 1434.24 (-CH₃, def), 1679.67 (C=N, str), 764.21 (C-Cl, str); ¹H NMR (DMSO-*d*₆, δ ppm): 12.7(s, 1H, -NH), 7.53 (s, 1H, -N=CH-), 7.35 (s, 1H, Ar-H), 7.31 (s, 5H), 7.2-7.18 (d, 2H, *J* = 10 Hz, Ar-H), 7.11-7.09 (d, 1H, *J* = 10 Hz, Ar-H); ¹³C NMR (DMSO-*d*₆, δ ppm): 161.1, 148.5, 145.2, 143.3, 135.7, 132.8, 131.4, 130.5, 130.5, 129.2, 129.2, 126.3, 121.7, 121.7, 118.2, 105.7; ESI mass (*m/z*): 329.02 (M⁺); Anal. (%) calcd. (found) for C₁₇H₁₃N₃Cl₂: C-61.83 (61.70), H- 3.97 (3.62), N-12.73 (12.51).

4-Chloro-N-((3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene)-3-nitrobenzenamine (6e): Yield: 78 %; m.p. 93-94 °C; IR (KBr, cm⁻¹): 2927.34 (-CH₃, str); 1515.02 (C-NO₂, str); 1436.14 (-CH₃, def), 1683.67 (C=N, str), 764.21 (C-Cl, str); ¹H NMR (DMSO-*d*₆, δ ppm): 12.17(s, 1H, -NH), 7.43 (s, 1H, -N=CH-), 7.37 (s, 1H, Ar-H), 7.31 (s, 5H), 7.21-7.18 (d, 2H, *J* = 15 Hz, Ar-H), 7.07-7.05 (d, 1H, *J* = 10 Hz, Ar-H); ¹³C NMR (DMSO-*d*₆, δ ppm): 161.6, 148.7, 145.2, 143.3, 135.7, 132.7, 131.4, 130.3, 130.3, 129.1, 129.1, 126.3, 121.7, 121.7, 118.5, 105.3; ESI-MS (*m/e*): 340.07 (M⁺). Anal. (%) calcd. (found) for C₁₇H₁₃N₄O₂Cl: C-59.92 (59.79), H-3.85 (3.81), N-16.44 (16.21).

3,4-Difluoro-N-((3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene)benzenamine (6f): Yield-68 %; m.p. 81-82 °C; IR (KBr, $\nu_{\max}$, cm⁻¹): 2925.14 (-CH₃, str), 1534.34 (C-NO₂, str), 1432.24 (-CH₃, def), 1681.67 (C=N, str), 1363.21 (C-F, str); ¹H NMR (DMSO-*d*₆, δ ppm): 13.17 (s, 1H, -NH), 7.41 (s, 1H, -N=CH-), 7.32 (s, 1H, Ar-H), 7.3 (s, 5H), 7.22-7.20 (d, 2H, *J* = 15 Hz, Ar-H), 7.17-7.15 (d, 1H, *J* = 10 Hz, Ar-H); ¹³C NMR (DMSO-*d*₆, δ ppm): 161.5, 148.5, 145.1, 143.2, 135.5, 132.1, 131.1, 130.7, 130.7, 129.1, 129.1, 126.3, 121.7, 121.7, 118.5, 105.4; ESI-MS (*m/e*): 297.07 (M⁺); Anal. (%) calcd. (found) for C₁₇H₁₃N₃F₂: C-68.68 (68.28), H-4.41 (3.51), N-14.13 (14.12).

2-Fluoro-N-((3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene)-5-nitrobenzenamine (6g): Yield-79 %; m.p. 93-94 °C; IR (KBr, $\nu_{\max}$, cm⁻¹): 2927.14 (-CH₃, str); 1534.34 (C-NO₂, str) 1433.24 (-CH₃, def); 1680.67 (C=N, str); 1160.21 (C-F, str). ¹H NMR (DMSO-*d*₆, δ ppm): 13.5 (s, 1H, -NH), 8.2-8.18 (d, 2H, *J* = 10 Hz, Ar-H), 7.75 (s, 1H, -N=CH-), 7.45 (s, 1H, Ar-H), 7.34 (s, 5H), 7.21-7.19 (d, 2H, *J* = 10 Hz, Ar-H); ¹³C NMR (DMSO-*d*₆, δ ppm): 163.5, 149.5, 146.1, 143.7, 135.7, 132.7, 131.1, 130.7, 130.7, 129.1, 129.1, 126.3, 121.5, 121.5, 118.5, 105.4; ESI-MS (*m/e*): 324.07 (M⁺); Anal. (%) calcd. (found) for C₁₇H₁₃N₄O₂F: C-62.96 (62.81), H- 4.04 (4.26), N-17.28 (17.11).

N-((3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene)-4-(trifluoromethyl)benzenamine (6h): Yield: 95 %; m.p. 101-

102 °C; IR (KBr, $\nu_{\max}$, cm^{-1}): 2927.14 ($-\text{CH}_3$, str), 1433.24 ($-\text{CH}_3$, def), 1670.67 ($\text{C}=\text{N}$, str), 1136.21 ($\text{C}-\text{F}$, str); ^1H NMR ($\text{DMSO}-d_6$, δ ppm): 13.7(s, 1H, $-\text{NH}$), 7.49 (s, 1H, $-\text{N}=\text{CH}-$), 7.37 (s, 5H), 7.21-7.18 (d, 2H, $J = 15$ Hz, Ar-H), 7.15 (s, 1H, Ar-H), 6.8-6.78 (d, 2H, $J = 10$ Hz, Ar-H); ^{13}C NMR ($\text{DMSO}-d_6$, δ ppm): 163.5, 149.5, 146.1, 143.7, 135.7, 132.7, 131.1, 130.7, 130.7, 129.1, 129.1, 126.3, 124.7, 121.5, 121.5, 118.5, 105.4; ESI-MS (m/e): 329.01 (M^+); Anal. (%) calcd. (found) for $\text{C}_{18}\text{H}_{14}\text{N}_3\text{F}_3$: C-65.65 (65.32), H-4.28 (3.39), N-12.76 (12.49).

N-[(3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]-4-nitro-3-(trifluoromethyl)benzenamine (6i): Yield-78 %; m.p. 108-110 °C; IR (KBr, $\nu_{\max}$, cm^{-1}): 2935.24 ($-\text{CH}_3$, str), 1413.02 ($\text{C}-\text{NO}_2$, str), 1336.24 ($-\text{CH}_3$, def), 1640.67 ($\text{C}=\text{N}$, str), 1330.21 ($\text{C}-\text{F}$, str); ^1H NMR ($\text{DMSO}-d_6$, δ ppm): 13.1 (s, 1H, $-\text{NH}$), 8.12-8.10 (d, 1H, $J = 10$ Hz, Ar-H), 7.7 (s, 1H, Ar-H), 7.62-7.60 (d, 1H, $J = 10$ Hz, Ar-H), 7.49 (s, 1H, $-\text{N}=\text{CH}-$), 7.31 (s, 5H), 7.25 (s, 1H, Ar-H); ^{13}C NMR ($\text{DMSO}-d_6$, δ ppm): 162.5, 149.3, 145.1, 142.7, 135.3, 132.7, 131.1, 130.2, 130.2, 129.3, 129.3, 126.3, 124.7, 121.5, 121.5, 118.5, 105; ESI-MS (m/e): 374.02 (M^+); Anal. (%) calcd. (found) for $\text{C}_{18}\text{H}_{13}\text{N}_4\text{O}_2\text{F}_3$: C-57.76 (57.46), H-4.28 (3.39), N-14.97 (14.59).

4-Methoxy-N-[(3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]benzenamine (6j): Yield-78 %; m.p. 95-96 °C; IR (KBr, $\nu_{\max}$, cm^{-1}): 2824.14 ($-\text{CH}_3$, str), 2815.22 ($-\text{OCH}_3$), 1432.24 ($-\text{CH}_3$, def), 1683.67 ($\text{C}=\text{N}$, str); ^1H NMR ($\text{DMSO}-d_6$, δ ppm): 13.7(s, 1H, $-\text{NH}$), 7.49 (s, 1H, $-\text{N}=\text{CH}-$), 7.35 (s, 5H), 7.21-7.18 (d, 2H, $J = 15$ Hz, Ar-H), 7.15 (s, 1H, Ar-H), 6.8-6.78 (d, 2H, $J = 10$ Hz, Ar-H), 3.73 (s, 3H); ^{13}C NMR ($\text{DMSO}-d_6$, δ ppm): 163.5, 149.5, 146.1, 143.7, 135.7, 132.7, 131.1, 130.7, 130.7, 129.1, 129.1, 126.3, 121.5, 121.5, 118.5, 105.4, 55.9; ESI-MS (m/e): 291.17 (M^+); Anal. (%) calcd. (found) for $\text{C}_{18}\text{H}_{17}\text{N}_3\text{O}$: C-74.20 (74.11), H-5.89 (5.62), N-14.42 (14).

Synthesis of 2-(3-methyl-1-phenyl-1H-pyrazol-4-yl)-3-phenylthiazolidin-4-one (7a-7j): The substituted imines (0.02 mole) were dissolved in toluene, SnCl_2 (0.05 mmol) was used as catalyst. After addition of thioglycolic acid (0.03 mole) reaction mixtures were stirred for an hour. The mixtures were then refluxed in water bath for 12 h and cooled at room temperature (Scheme-I). Excess solvent were removed by distillation and compounds were dissolved in dichloromethane. The organic layer were washed with 10 % sodium-bicarbonate and finally with brine solutions, dried over sodium sulphate and evaporated to dryness. Purification of the compounds were done with petroleum ether and chloroform (2:8 v/v) by chromatographic technique.

3-(4-Chlorophenyl)-2-(3-methyl-1-phenyl-1H-pyrazol-4-yl)thiazolidin-4-one (7a): Yield-68 %; m.p. 143-144 °C; IR (KBr, $\nu_{\max}$, cm^{-1}): 2959.34 ($-\text{CH}_3$, str), 1775.67 ($\text{C}=\text{O}$, str), 1455.14 ($-\text{CH}_3$, def), 1260.33 ($\text{C}-\text{N}$, str), 760.21 ($\text{C}-\text{Cl}$, str); ^1H NMR ($\text{DMSO}-d_6$, δ ppm): 13.5 (s, 1H, $-\text{NH}$), 7.33 (s, 5H), 7.2-7.18 (d, 2H, $J = 10$ Hz, Ar-H), 7.15 (s, 1H, Ar-H), 6.8-6.78 (d, 2H, $J = 10$ Hz, Ar-H), 4.85 (s, 1H, CH-N), 3.49 (s, 1H, $\text{CH}_2-\text{C}=\text{O}$), 3.24 (s, 1H, $\text{CH}_2-\text{C}=\text{O}$); ^{13}C NMR ($\text{DMSO}-d_6$, δ ppm): 170.9, 147.1, 145.5, 141.4, 139.7, 132.8, 131.4, 130.2, 130.2, 129.4, 129.4, 126.3, 123.7, 123.7, 120.2, 105, 45, 45, 11; ESI-MS (m/e): 369.17 (M^+); Anal. (%) calcd. (found) for $\text{C}_{19}\text{H}_{16}\text{N}_3\text{OSCl}$: C-61.70 (61.66), H-4.36 (4.19), N-11.36 (11.12).

Entry	R	Entry	R	Entry	R
6a,7a	4-chloro	6e,7e	3-nitro-4-chloro	6h,7h	4-trifluoromethyl
6b,7b	4-bromo	6f,7f	3,4-difluoro	6i,7i	3-trifluoro-4-nitro
6c,7c	4-nitro	6g,7g	2-fluoro-5-nitro	6j,7j	4-methoxy
6d,7d	3,4-dichloro				

Scheme-I

3-(4-Bromophenyl)-2-(3-methyl-1-phenyl-1H-pyrazol-4-yl)thiazolidin-4-one (7b): Yield-66 %; m.p. 133-134 °C; IR (KBr, $\nu_{\max}$, cm^{-1}): 2953.24 ($-\text{CH}_3$, str), 1692.61 ($\text{C}=\text{O}$, str), 1463.14 ($-\text{CH}_3$, def), 1310.33 ($\text{C}-\text{N}$, str), 667.21 ($\text{C}-\text{Br}$, str); ^1H NMR ($\text{DMSO}-d_6$, δ ppm): 12.5 (s, 1H, $-\text{NH}$), 7.31 (s, 5H), 7.21-7.19 (d, 2H, $J = 10$ Hz, Ar-H), 7.17 (s, 1H, Ar-H), 6.81-6.79 (d, 2H, $J = 10$ Hz, Ar-H), 4.81 (s, 1H, CH-N), 3.47 (s, 1H, $\text{CH}_2-\text{C}=\text{O}$), 3.22 (s, 1H, $\text{CH}_2-\text{C}=\text{O}$), 2.70 (s, 3H, $-\text{CH}_3$); ^{13}C NMR ($\text{DMSO}-d_6$, δ ppm): 171.9, 147.2, 146.5, 142.4, 139.5, 132.7, 131.3, 130.1, 130.1, 129.3, 129.3, 126.7, 123.8, 123.8, 120.1, 105.3, 45.1, 45.1, 11; ESI-MS (m/e): 415.02 (M^+); Anal. (%) calcd. (found) for $\text{C}_{13}\text{H}_{12}\text{N}_3\text{OSBr}$: C-55.08 (54.96), H-3.89 (3.69), N-10.14 (9.92).

2-(3-Methyl-1-phenyl-1H-pyrazol-4-yl)-3-(4-nitrophenyl)thiazolidin-4-one (7c): Yield-76 %; m.p. 138-139 °C; IR (KBr, cm^{-1}): 2949.24 ($-\text{CH}_3$, str), 1701.61 ($\text{C}=\text{O}$, str), 1525.02 ($\text{C}-\text{NO}_2$, str), 1461.34 ($-\text{CH}_3$, def), 1321.33 ($\text{C}-\text{N}$, str); ^1H NMR ($\text{DMSO}-d_6$, δ ppm): 13.7 (s, 1H, $-\text{NH}$), 7.31 (s, 5H), 7.21-7.21 (d, 2H, $J = 10$ Hz, Ar-H), 7.15 (s, 1H, Ar-H), 6.82-6.80 (d, 2H, $J = 10$ Hz, Ar-H), 4.85 (s, 1H, CH-N), 3.43 (s, 1H, $\text{CH}_2-\text{C}=\text{O}$), 3.22 (s, 1H, $\text{CH}_2-\text{C}=\text{O}$); ^{13}C NMR ($\text{DMSO}-d_6$, δ ppm): 171.3, 147.1, 146.3, 141.4, 138.5, 132.5, 131.4, 130.5, 130.5, 129.5, 129.5, 127.7, 124.8, 124.8, 120.1, 105.3, 45.3, 45.3, 11.1; ESI-MS (m/e): 380.09 (M^+); Anal. (%) calcd. (found) for $\text{C}_{19}\text{H}_{16}\text{N}_4\text{O}_3\text{S}$: C-59.99 (59.70), H-4.24 (4.49), N-14.74 (14.51).

3-(3,4-Dichlorophenyl)-2-(3-methyl-1-phenyl-1H-pyrazol-4-yl)thiazolidin-4-one (7d): Yield-68 %; m.p. 110-111 °C; IR (KBr, $\nu_{\max}$, cm^{-1}): 2948.24 ($-\text{CH}_3$, str), 1720.61 ($\text{C}=\text{O}$, str), 1471.14 ($-\text{CH}_3$, def), 1321.33 ($\text{C}-\text{N}$, str), 764.21 ($\text{C}-\text{Cl}$, str); ^1H NMR ($\text{DMSO}-d_6$, δ ppm): 12.7 (s, 1H, $-\text{NH}$), 7.45 (s, 1H, Ar-H), 7.33 (s, 5H), 7.2-7.18 (d, 2H, $J = 10$ Hz,

Ar-H), 7.11-7.09 (d, 1H, $J = 10$ Hz, Ar-H), 4.83 (s, 1H, CH-N), 3.41 (s, 1H, CH₂-C=O); 3.22 (s, 1H, CH₂-C=O); ¹³C NMR (DMSO-*d*₆, δ ppm): 170.3, 146.1, 143.3, 141.2, 133.5, 132.7, 131.3, 130.2, 130.2, 129.5, 129.5, 126.7, 123.8, 123.8, 120.1, 108.3, 47.3, 47.3, 11.1; ESI-MS (m/e): 403.15 (M^+); Anal. (%) calcd. (found) for C₁₉H₁₅N₃OSCl₂: C-56.44 (56.12), H-3.74 (3.42), N-10.39 (10.11).

3-(4-Chloro-3-nitrophenyl)-2-(3-methyl-1-phenyl-1H-pyrazol-4-yl)thiazolidin-4-one (7e): Yield-63 %; m.p. 149-150 °C; IR (KBr, $\nu_{\max}$, cm⁻¹): 2948.24 (-CH₃, str), 1720.61 (C=O, str), 1525.02 (C-NO₂, str), 1471.14 (-CH₃, def), 1321.33 (C-N, str), 764.21 (C-Cl, str); ¹H NMR (DMSO-*d*₆, δ ppm): 12.3 (s, 1H, -NH), 7.43 (s, 5H), 7.35 (s, 1H, Ar-H), 7.2-7.18 (d, 2H, $J = 10$ Hz, Ar-H), 7.11-7.09 (d, 1H, $J = 10$ Hz, Ar-H), 4.85 (s, 1H, CH-N), 3.49 (s, 1H, CH₂-C=O), 3.25 (s, 1H, CH₂-C=O); ¹³C NMR (DMSO-*d*₆, δ ppm): 170.3, 146.1, 143.3, 141.2, 133.5, 132.7, 131.3, 130.2, 130.2, 129.5, 129.5, 126.7, 123.8, 123.8, 120.1, 108.3, 47.3, 47.3, 11.1; ESI-MS (m/e): 414.08 (M^+); Anal. (%) calcd. (found) for C₁₉H₁₅N₄O₃SCl: C-55.01 (54.80), H-3.64 (3.45), N-13.50 (13.11).

3-(3,4-Difluorophenyl)-2-(3-methyl-1-phenyl-1H-pyrazol-4-yl)thiazolidin-4-one (7f): Yield: 63 %; m.p. 163-164 °C; IR (KBr, cm⁻¹): 2948.24 (-CH₃, str), 1720.61 (C=O, str), 1471.14 (-CH₃, def), 1321.33 (C-N, str), 1201 (C-F, str); ¹H NMR (DMSO-*d*₆, δ ppm): 12.37 (s, 1H, -NH), 7.32 (s, 1H, Ar-H), 7.29 (s, 5H), 7.23-7.21 (d, 2H, $J = 10$ Hz, Ar-H), 7.11-7.09 (d, 1H, $J = 10$ Hz, Ar-H), 4.83 (s, 1H, CH-N), 3.48 (s, 1H, CH₂-C=O), 3.15 (s, 1H, CH₂-C=O); ¹³C NMR (DMSO-*d*₆, δ ppm): 171.3, 145.1, 143.7, 141.3, 135.5, 133.7, 131.8, 130.2, 130.2, 127.5, 127.5, 125.7, 121.8, 121.8, 120.1, 108.3, 45.3, 45.3, 11.4; ESI-MS (m/e): 371.12 (M^+); Anal. (%) calcd. (found) for C₁₉H₁₅N₃OSF₂: C-61.44 (61.11), H-4.07 (3.82), N-11.31 (11.11).

3-(2-Fluoro-5-nitrophenyl)-2-(3-methyl-1-phenyl-1H-pyrazol-4-yl)thiazolidin-4-one (7g): Yield: 69 %; m.p. 131-132 °C; IR (KBr, $\nu_{\max}$, cm⁻¹): 2927.14 (-CH₃, str), 1720.61 (C=O, str), 1534.34 (C-NO₂, str), 1321.33 (C-N, str), 1433.24 (-CH₃, def), 1160.21 (C-F, str); ¹H NMR (DMSO-*d*₆, δ ppm): 13.5 (s, 1H, -NH), 8.2-8.18 (d, 2H, $J = 10$ Hz, Ar-H), 7.45 (s, 1H, Ar-H), 7.39 (s, 5H), 7.21-7.19 (d, 2H, $J = 10$ Hz, Ar-H), 4.81 (s, 1H, CH-N), 3.43 (s, 1H, CH₂-C=O), 3.15 (s, 1H, CH₂-C=O); ¹³C NMR (DMSO-*d*₆, δ ppm): 170.3, 146.1, 143.3, 141.2, 133.5, 132.7, 131.3, 130.2, 130.2, 129.5, 129.5, 126.7, 123.8, 123.8, 120.1, 108.3, 47.3, 47.3, 11.1; ESI-MS (m/e): 398.11 (M^+); Anal. (%) calcd. (found) for C₁₉H₁₅N₄O₃SF: C-57.28 (57.11), H-3.79 (3.66), N-14.06 (13.96).

2-(3-Methyl-1-phenyl-1H-pyrazol-4-yl)-3-(4-(trifluoromethyl)phenyl)thiazolidin-4-one (7h): Yield: 65 %; m.p. 125-127 °C; IR (KBr, $\nu_{\max}$, cm⁻¹): 2927.14 (-CH₃, str), 1720.61 (C=O, str), 1321.33 (C-N, str), 1433.24 (-CH₃, def), 1160.21 (C-F, str); ¹H NMR (DMSO-*d*₆, δ ppm): 13.7 (s, 1H, -NH), 7.33 (s, 5H), 7.21-7.18 (d, 2H, $J = 15$ Hz, Ar-H), 7.15 (s, 1H, Ar-H), 6.8-6.78 (d, 2H, $J = 10$ Hz, Ar-H), 4.81 (s, 1H, CH-N), 3.43 (s, 1H, CH₂-C=O), 3.15 (s, 1H, CH₂-C=O); ¹³C NMR (DMSO-*d*₆, δ ppm): 170.3, 146.1, 143.3, 141.2, 133.5, 132.7, 131.3, 130.2, 130.2, 129.5, 129.5, 126.7, 124.7, 123.8, 123.8, 120.1, 108.3, 47.3, 47.3, 11.1; ESI-MS (m/e): 403.12 (M^+); Anal. (%) calcd. (found) for C₂₀H₁₆N₃OSF₃: C-59.54 (59.42), H-4 (3.81), N-10.42 (10.19).

2-(3-Methyl-1-phenyl-1H-pyrazol-4-yl)-3-[4-nitro-3-(trifluoromethyl)phenyl]thiazolidin-4-one (7i): Yield: 88 %; m.p. 153-154 °C; IR (KBr, cm⁻¹): 2925.24 (-CH₃, str), 1720.61 (C=O, str), 1513.02 (C-NO₂, str), 1436.24 (-CH₃, def), 1330.21 (C-F, str), 1321.33 (C-N, str); ¹H NMR (DMSO-*d*₆, δ ppm): 13.1 (s, 1H, -NH), 8.12-8.10 (d, 1H, $J = 10$ Hz, Ar-H), 7.7 (s, 1H, Ar-H), 7.62-7.60 (d, 1H, $J = 10$ Hz, Ar-H), 7.41 (s, 5H), 7.25 (s, 1H, Ar-H), 2.39 (s, 3H, -CH₃), 4.81 (s, 1H, CH-N), 3.43 (s, 1H, CH₂-C=O), 3.15 (s, 1H, CH₂-C=O); ¹³C NMR (DMSO-*d*₆, δ ppm): 170.3, 146.1, 143.3, 141.2, 133.5, 132.7, 131.3, 130.2, 130.2, 129.5, 129.5, 126.7, 124.7, 123.8, 123.8, 120.1, 108.3, 47.3, 47.3, 11.1; ESI-MS (m/e): 448.07 (M^+); Anal. (%) calcd. (found) for C₂₀H₁₅N₄O₃SF₃: C-53.57 (53.35), H-3.53 (3.46), N-12.49 (12.27).

3-(4-Methoxyphenyl)-2-(3-methyl-1-phenyl-1H-pyrazol-4-yl)thiazolidin-4-one (7j): Yield-78 %; m.p. 137-138 °C; IR (KBr, $\nu_{\max}$, cm⁻¹): 2924.14 (-CH₃, str), 2855.22 (-OCH₃), 1730.21 (C=O, str), 1432.24 (-CH₃, def), 1321.33 (C-N, str); ¹H NMR (DMSO-*d*₆, δ ppm): 13.7 (s, 1H, -NH), 7.49 (s, 1H, -N=CH-), 7.37 (s, 5H), 7.21-7.18 (d, 2H, $J = 15$ Hz, Ar-H), 7.15 (s, 1H, Ar-H), 6.8-6.78 (d, 2H, $J = 10$ Hz, Ar-H), 4.81 (s, 1H, CH-N), 3.73 (s, 3H), 3.43 (s, 1H, CH₂-C=O), 3.15 (s, 1H, CH₂-C=O); ¹³C NMR (DMSO-*d*₆, δ ppm): 170.3, 146.1, 143.3, 141.2, 133.5, 132.7, 131.3, 130.2, 130.2, 129.5, 129.5, 126.7, 124.7, 123.8, 123.8, 120.1, 108.3, 55.1, 47.3, 47.3, 11.1; ESI-MS (m/e): 365.17 (M^+); Anal. (%) calcd. (found) for C₂₀H₁₉N₃O₂S: C-65.73 (65.66), H-5.24 (5.11), N-11.50 (11.38).

Pharmacology

Antioxidant activity: The *in vitro* antioxidant activity was determined by 1,1-diphenyl-2-picrylhydrazyl radical method, which was used to evaluate the free radical scavenging capacity of different antioxidants^{11,12}.

Animals: Wister rat of either sex weighing between 180-200 g were taken for anti diabetic activity. Animals were maintained under standard environmental condition at temperature of 22 ± 2 °C and 45-50 % relative humidity for 24 h each of dark and light cycle with proper diet. All the studies were done according to protocol approved by Institutional Animal Ethical Committee (IAEC) of Bansal College of Pharmacy (Reg. no-1252/ac/10/CPCSEA, Ref. no-BCP/IAEC/12/02).

Acute toxicity study: The acute oral toxicity study was carried out according to OECD guideline no 423 in wister rats¹³. The doses were fixed 2 mg/kg (p.o) to 10 mg/kg (p.o) for rats and contain 5 in each group. The mortality and general behaviours were under observation for 14 days. The test compounds were nontoxic in the dose of 5 mg/kg body weight.

Antidiabetic activity

Oral glucose tolerance test on rat (OGTT): Twelve groups of animals were administered normal saline at the dose of 5 mg/kg for test compounds followed by administration of glucose solution in the dose of 2g/kg. After 0.5 h of administration of drug blood sample were withdrawn from dorsal vein at interval of 60, 120 and 180 min¹⁴. Blood glucose level were estimated using blood glucose test strip with elegance glucometer (Frankenbeng Germany) & GOD-POD kit (Acuurex, India).

Induction of diabetes: Streptazocine (STZ) was used in the dose of 60 mg/kg to induce insulin dependent diabetes. streptazocine was injected into rats intraperitoneally. After 48 h of administration of streptazocine, the blood samples were collected by dorsal vein for determination of blood glucose level. The rat¹⁵ with fasting glucose level in range of 275-300 mg/100 mL - considered as diabetic and considered for study.

Experimental protocol and dose schedule: The total periods for conductance of study were 21 days. The rats were divided into 13 groups consisting of 06 animals in each group.

Group-1: Normal rats treated with normal saline 10 mL/kg p.o.

Group-2: Diabetic control treated with streptazocine (60 mg/kg) dissolved in citrate buffer.

Group-3: Diabetic rat treated with rosiglitazone 8 mg/kg.

Group-4-13: Diabetic rat treated with test compounds at 5 mg/kg body weight.

On 1,7,14 and 21 days of study after 2 h of oral administration of test compounds blood glucose levels and body weight were measured. Blood samples were withdrawn through dorsal vein. On 21 days whole blood was collected by cardiac puncture. Blood sample collected then centrifuged at 3000 rpm for 10 min after to obtain serum. Blood glucose levels were estimated by GOD-POD kit (Accurex, India). All biochemical parameters were determined. Total cholesterol¹⁶, triglyceride by Hantzsch condensation method¹⁷, serum urea and creatinine by method of Thomas¹⁸, total protein¹⁹, HDL cholesterol²⁰ were measured.

Statistical analysis: The results were shown as Mean $\pm$ SEM and comparison between standard and test compounds were made by one way ANOVA followed by Dunnetts test. Values of $p \leq 0.001$ were considered as significant.

RESULTS AND DISCUSSION

The present work involves cyclization of Schiff bases to thiazolidine-4-ones derivatives. The Schiff bases (**6a-6j**) were obtained by the reaction between electrophilic carbon atom of substituted pyrazole-4-aldehyde and nucleophilic nitrogen atom of substituted amines. The preparation of thiazolidine-4-ones (**7a-7j**) proceeds by an attack of sulphur nucleophile of thioglycolic acid on imine carbon followed by intramolecular cyclization. During reaction one mole of water was eliminated. $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ acted as acid catalyst which counters balance between nucleophilicity and acidity for completion of reaction. The substitution with electron donating group at

para and *meta* position of ring increases percentage yield where as it decreases in case of *ortho* substitution due to steric effect. Purification of compounds were done using hexane: chloroform (2:8 v/v) for thiazolidine-4-ones by column chromatography.

The formations of compounds were again confirmed by elemental analysis (C, H, N analysis). In view of establishment of structure spectral analysis has been performed by IR, ¹H NMR, ¹³C NMR and mass analysis. The IR peaks at 1775.51-1701.61, 1685-1624, 1321.33-1260.33 and 1290-1200 cm^{-1} indicate presence of C=O, C=N, C-N groups in synthesized compounds. The characteristic ¹H NMR peaks at δ values 4.85-4.81, 3.49-3.43 and 3.25-3.15 ppm indicate presence of thiazolidine-4-ones. The aromaticity of the compounds was also confirmed by ¹H NMR. The ¹³C NMR spectral data also describe characteristic peak according to proposed structure. From the mass spectral analysis it was found that *m/e* peaks according to calculated molecular mass of the synthesized compounds.

Biological evaluation: *in vitro* Antioxidant activity was determined by DPPH method. The DPPH assay method is based on the reduction of DPPH, a stable free radical. The free radical DPPH with an odd electron gives a maximum absorption at 517 nm. When a solution of DPPH is mixed with that of a substance that can donate a hydrogen atom, then this gives rise to the reduced form with the loss of this violet colour¹². It is well established that electron donating groups stabilize the resulted phenoxyl radicals through inductive resonance effect; thus lower the OH bond energy and enhance the radical scavenging activity. In contrary, electron withdrawing groups stabilize more the phenols and destabilize the resulted radicals. In addition, a hydrogen bonding could be formed between the phenoxyl unpaired electron and the adjacent hydroxyl group that stabilizes the radicals formed more than it does for the parent diols. Ascorbic acid is good antioxidant and exhibited high activity reached 99.1 %. It could also undergo the two hydrogen-atom transfer process to give the dehydroascorbic acid. Due to this reason the compounds with electron donating groups **7a**, **7b**, **7d**, **7f**, **7h** had shown more IC₅₀ values compare to standard ascorbic acid. Whereas compounds with electron withdrawing groups shown group have shown less IC₅₀ value compare to standard (Table-1).

The acute toxicity study was performed. The study has shown that at 5 mg/kg body weight the compounds are nontoxic.

TABLE-1
OBSERVATION FOR ANTIOXIDANT ACTIVITY IN TERMS OF DPPH METHOD

Compound code	DPPH scavenging effect (%) [mean $\pm$ SEM]				
	25 $\mu\text{g/mL}$	50 $\mu\text{g/mL}$	75 $\mu\text{g/mL}$	100 $\mu\text{g/mL}$	125 $\mu\text{g/mL}$
7a	35.61 $\pm$ 0.060	51.31 $\pm$ 0.026	63.41 $\pm$ 0.098	76.97 $\pm$ 0.150	97.32 $\pm$ 0.026
7b	38.06 $\pm$ 0.010	58.56 $\pm$ 0.060	73.91 $\pm$ 0.050	82.75 $\pm$ 0.120	96.20 $\pm$ 0.140
7c	19.21 $\pm$ 0.120	21.37 $\pm$ 0.090	38.22 $\pm$ 0.240	43.44 $\pm$ 0.150	56.53 $\pm$ 0.160
7d	32.39 $\pm$ 0.050	45.63 $\pm$ 0.025	57.24 $\pm$ 0.160	76.52 $\pm$ 0.052	93.70 $\pm$ 0.010
7e	28.83 $\pm$ 0.098	34.95 $\pm$ 0.026	55.00 $\pm$ 0.023	69.24 $\pm$ 0.050	75.01 $\pm$ 0.110
7f	37.26 $\pm$ 0.250	49.56 $\pm$ 0.130	60.40 $\pm$ 0.160	81.50 $\pm$ 0.090	97.47 $\pm$ 0.120
7g	24.10 $\pm$ 0.130	32.12 $\pm$ 0.250	49.11 $\pm$ 0.120	52.97 $\pm$ 0.010	65.19 $\pm$ 0.110
7h	15.00 $\pm$ 0.120	28.23 $\pm$ 0.010	35.31 $\pm$ 0.180	45.01 $\pm$ 0.080	52.11 $\pm$ 0.140
7i	15.10 $\pm$ 0.170	20.11 $\pm$ 0.050	32.03 $\pm$ 0.200	45.80 $\pm$ 0.030	51.00 $\pm$ 0.080
7j	28.44 $\pm$ 0.030	47.09 $\pm$ 0.120	51.89 $\pm$ 0.140	75.60 $\pm$ 0.210	96.48 $\pm$ 0.120
STD (ascorbic acid)	22.28 $\pm$ 0.120	41.03 $\pm$ 0.190	52.06 $\pm$ 0.200	75.02 $\pm$ 0.090	96.10 $\pm$ 0.180

The antidiabetic activity was performed by using streptozotocin (STZ) induced model in wister rat. Streptozotocin enters the pancreatic cell *via* a glucose transporter GLUT2 and causes alkylation of deoxyribonucleic acid. Streptozotocin induces activation of poly adenosine ribosylation and nitric oxide release. Due to destruction of pancreatic cells by streptazocine a huge release of insulin which makes animals more susceptible to severe hypoglycemia that may be lethal. Due to this reason animal treated with streptazocine were administered with 5 % glucose solution for 12-24 h. Afterwards, an increase of glucose levels was observed in comparison to control animals due to insulin deficiency (Table-2)¹⁵. The thiazolidine were dependent on the presence of insulin for activity. However, they do not affect insulin secretion. The thiazolidine were highly selective

and potent agonists for the peroxisome proliferator activated receptor (PPAR) γ that regulates the transcription of a number of insulin responsive genes. Activation of PPAR- γ -receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport and utilization. Additionally, PPAR- γ responsive genes also play a role in the regulation of fatty acid metabolism. Unlike oral sulfonylureas, rosiglitazone enhances tissue sensitivity to insulin rather than stimulates insulin secretion²¹. Blood glucose levels in rats administered with 2 g/kg glucose were significantly decreased by test compounds with in 1 h as compared to standard group. Treatment with compounds **7a-7j** has shown that there are significant fall of blood glucose level compared to standard rosiglitazone on 21 day of study. But on 21 day of treatment it

TABLE-2
ANTIDIABETIC ACTIVITY LONG TERM EFFECT OF STANDARD (8 MG/KG BODY wt.)
AND COMPOUNDS (5 mg/kg BODY wt.) ON BLOOD GLUCOSE LEVEL OF RAT

Compound No.	0 min	60 min	120 min	180 min
OGTT blood glucose level (mg/dl)				
Control	91.5 $\pm$ 2.23	106.2 $\pm$ 3.02	103 $\pm$ 7	93.67 $\pm$ 1.00
Rosiglitazone	91.5 $\pm$ 2.23	110.0 $\pm$ 3.94	108 $\pm$ 1.89	97.83 $\pm$ 0.47***
7a	93.83 $\pm$ 0.6	152.2 $\pm$ 7.34	132 $\pm$ 0.85	90.83 $\pm$ 0.47***
7b	91.2 $\pm$ 2.21	126.3 $\pm$ 1.23	115 $\pm$ 2.6	93.5 $\pm$ 2.46***
7c	93.83 $\pm$ 0.6	182.7 $\pm$ 1.5	143.3 $\pm$ 3.12	93.5 $\pm$ 2.46
7d	92.2 $\pm$ 1.21	120.1 $\pm$ 1.23	113.2 $\pm$ 2.3	96.5 $\pm$ 2.46**
7e	90.5 $\pm$ 2.11	126.3 $\pm$ 1.23	110.1 $\pm$ 1.6	93.5 $\pm$ 2.46**
7f	91.2 $\pm$ 2.21	126.3 $\pm$ 1.23	114.2 $\pm$ 2.6	93.5 $\pm$ 2.46
7g	91.2 $\pm$ 2.21	126.3 $\pm$ 1.23	115.3 $\pm$ 2.6	110.5 $\pm$ 2.46**
7h	96.33 $\pm$ 0.98	191.8 $\pm$ 4.7	149.2 $\pm$ 2.38	95 $\pm$ 1.82***
7i	96.33 $\pm$ 0.98	191.8 $\pm$ 4.7	149.2 $\pm$ 2.38	96.12 $\pm$ 1.82**
7j	92.62 $\pm$ 0.87	153.2 $\pm$ 1.23	130 $\pm$ 2.4	94.3 $\pm$ 2.12***
Compound No.	0 days	7 days	14 days	21 days
Fasting blood glucose level (mg/dl)				
Control	91 $\pm$ 1.00	115.7 $\pm$ 3.9	114 $\pm$ 6.8	100 $\pm$ 2.47
Diabetic control	244.7 $\pm$ 2.96	281.3 $\pm$ 2.51	311 $\pm$ 3.99	336 $\pm$ 2.12
Rosiglitazone	311.3 $\pm$ 3.99	247.8 $\pm$ 7.4	126.7 $\pm$ 5.8	106.5 $\pm$ 1.9
7a	301.7 $\pm$ 3.07	152.5 $\pm$ 1.2	132.2 $\pm$ 1.65	97.83 $\pm$ 0.87***
7b	285 $\pm$ 4.8	136.7 $\pm$ 2.04	124.5 $\pm$ 1.60	95.33 $\pm$ 1.33***
7c	301.7 $\pm$ 3.07	123.2 $\pm$ 0.94	119.5 $\pm$ 1.04	112.12 $\pm$ 2.26
7d	311.7 $\pm$ 3.07	120.1 $\pm$ 0.84	116.5 $\pm$ 1.04	105.12 $\pm$ 2.26**
7e	281.7 $\pm$ 3.07	113.2 $\pm$ 0.93	115.5 $\pm$ 1.04	103.12 $\pm$ 2.26**
7f	2911.7 $\pm$ 3.07	125.1 $\pm$ 0.92	114.5 $\pm$ 1.04	101.12 $\pm$ 2.26**
7g	312.7 $\pm$ 3.07	124.2 $\pm$ 0.91	113.5 $\pm$ 1.04	105.32 $\pm$ 2.26
7h	250.3 $\pm$ 8.51	132.8 $\pm$ 3.19	124.5 $\pm$ 1.29	87 $\pm$ 3.48***
7i	253.3 $\pm$ 8.51	142.8 $\pm$ 3.19	121.5 $\pm$ 1.29	104 $\pm$ 3.48**
7j	286.5 $\pm$ 1.19	193 $\pm$ 3.73	120 $\pm$ 1.89	96.11 $\pm$ 2.26***
Change in bodyweight (gm)				
Control	160 $\pm$ 0.6	169 $\pm$ 0.5	166 $\pm$ 0.8	163 $\pm$ 0.2
Diabetic control	178.5 $\pm$ 0.99	190 $\pm$ 0.69	215 $\pm$ 0.56	253 $\pm$ 0.12
Rosiglitazone	171 $\pm$ 0.39	144.5 $\pm$ 0.67	141 $\pm$ 0.60	169 $\pm$ 0.6
7a	168 $\pm$ 0.51	141 $\pm$ 0.6	137 $\pm$ 0.4	162 $\pm$ 0.3***
7b	169 $\pm$ 0.66	132 $\pm$ 0.25	142 $\pm$ 0.7	156 $\pm$ 0.2***
7c	165 $\pm$ 0.6	158 $\pm$ 0.7	143 $\pm$ 0.46	148 $\pm$ 0.2
7d	163 $\pm$ 0.6	148 $\pm$ 0.7	157 $\pm$ 0.41	159 $\pm$ 0.2**
7e	162 $\pm$ 0.4	138 $\pm$ 0.7	153 $\pm$ 0.46	161 $\pm$ 0.2**
7f	164 $\pm$ 0.3	157 $\pm$ 0.7	153 $\pm$ 0.46	159.1 $\pm$ 0.2**
7g	167 $\pm$ 0.2	154 $\pm$ 0.7	153 $\pm$ 0.46	165 $\pm$ 0.2
7h	170 $\pm$ 0.21	161 $\pm$ 0.4	155 $\pm$ 0.3	168 $\pm$ 0.2***
7i	169 $\pm$ 0.21	161 $\pm$ 0.4	153 $\pm$ 0.3	168 $\pm$ 0.2**
7j	168 $\pm$ 0.4	123 $\pm$ 0.61	141 $\pm$ 0.52	159 $\pm$ 0.67***

Data analyzed by one-way ANOVA followed by Dunnett's test (n = 6). ***P $\leq$ 0.001 were considered as significant. **P $\leq$ 0.05 were considered as moderate in activity

TABLE-3
BIOCHEMICAL PARAMETER OF RAT

Compound No. group (mg/kg body wt.)	Cholesterol (mg/dl)	Triglycerides (mg/dl)	Creatinin (mg/dl)	Urea (mg/dl)	HDL Cholesterol (mg/dl)	Total Protein (g/dl)
Control	148 ± 1.5	83.3 ± 4.6	0.6 ± 0.4	22 ± 0.4	34.1 ± 1.8	8.3 ± 1.7
Diabetic control	290 ± 1.9	258 ± 9.8	2 ± 1.9	80 ± 3.2	28 ± 1.8	4 ± 3.2
Rosiglitazone(8)	119 ± 2.8	101 ± 5.2	0.41 ± 1	32.2 ± 3.1	63 ± 2.9	8.4 ± 0.4
7a (5)	136.8 ± 0.7***	137 ± 1***	0.77 ± 0.1***	25.67 ± 0.61***	32.33 ± 2.41***	7.7 ± 0.8***
7b (5)	144.5 ± 0.8***	138 ± 1***	0.47 ± 0.01***	23.67 ± 0.42***	36.17 ± 0.94***	7.6 ± 0.3***
7c (5)	143.8 ± 1.2	123 ± 1.11	0.63 ± 0.01	24.17 ± 1.02	38.5 ± 2.34	7.2 ± 0.1
7d (5)	156.8 ± 1.1**	123 ± 1.11**	0.53 ± 0.01**	29.17 ± 1.02**	58.5 ± 2.34**	5.8 ± 0.1**
7e (5)	190.7 ± 1.3**	111.1 ± 1.11**	0.50 ± 0.01**	34.17 ± 1.02**	48.5 ± 2.34**	4.2 ± 0.1**
7f (5)	142.8 ± 1.2**	133.2 ± 1.11**	0.65 ± 0.01**	33.17 ± 1.02**	48.5 ± 2.34**	5.7 ± 0.1**
7g (5)	173.8 ± 1.2	123 ± 1.11	0.73 ± 0.01	54.17 ± 1.02	42.5 ± 2.34	3.2 ± 0.1
7h (5)	149.8 ± 1.19***	125.5 ± 1.6***	0.56 ± 0.06***	26.17 ± 0.03***	33.83 ± 1.53***	6.9 ± 0.1***
7i (5)	141.1 ± 1.7**	131.23 ± 1.3**	0.61 ± 0.03**	29.17 ± 0.02**	43.83 ± 1.53**	5.3 ± 0.1**
7j (5)	150.5 ± 2.23***	152 ± 2.5***	0.55 ± 0.08***	23.17 ± 0.7***	30.86 ± 3.10***	7.0 ± 1.3***

Data analyzed by one-way ANOVA followed by Dunnett's test (n = 6). ***P ≤ 0.001 were considered as significant. **P ≤ 0.05 were considered as moderate in activity

was found that there is significant gain of body weight specially the rat treated with test compound. There was decrease in serum cholesterol, triglyceride, creatinine, urea levels are decreased significantly where as the HDL level and total protein levels are found to increase after 21 days treatment. But out of all the compounds tested **7a**, **7b**, **7h**, **7j** shown more significant antidiabetic effect against hyperglycemic rats but there is no significant effect found in case of normoglycemic condition. Whereas compounds **7d**, **7e**, **7f**, **7g**, **7i** have shown moderate activity and compounds **7c**, **7g** were not significant (Table-3).

From the SAR study it was confirmed that presence of thiazolidine-4-one nucleus along with pyrazole nucleus is essential for both antioxidant and antidiabetic activity. But overall effect depends upon substitution on phenyl ring attached to thiazolidine nucleus. Compounds with *para* substitution are potent, where as compound with *para* and *meta* substitution shown moderate activity. The *ortho* substituted compounds are not potent. It were also confirmed that electron withdrawing substituents at *para* or *meta* position decrease the potency of compounds.

Conclusion

The structure of synthesized 2-(3-methyl-1-phenyl-1H-pyrazol-4-yl)-3-phenylthiazolidin-4-ones were confirmed by spectral and elemental analysis. It was found that compounds **7a**, **7b**, **7h**, **7j** are more potent antioxidant and antidiabetic activity compared to standard ascorbic acid and rosiglitazone. This might be due to thiazolidine-4-one nucleus present along with pyrazole ring. It was also found that phenyl ring substitution have great effect on biological activity. In compounds, the substitutions on phenyl ring at *para* position with electron donating groups have shown potent activity compare to standards.

ACKNOWLEDGEMENTS

The authors acknowledge to IIMT College of Medical Sciences; Regional Institute of Pharmaceutical sciences and Technology, Govt of Tripura; AIRF, JNU, New Delhi and Arbro

Lab, New Delhi. The authors also wish to acknowledge Arunabaha Mallik, Assistant Professor, Bansal College of Pharmacy, Bhopal for providing the facility for animal study.

REFERENCES

1. E.M. Sharshira and N.M.M. Hamada, *Molecules*, **17**, 4962 (2012).
2. M.R. Chaurasia, *Indian J. Pharm.*, **33**, 17 (1971).
3. B. Zimenkovsky, R. Lesyk, O. Vladzimirska, I. Nektgayev, S. Golota and I. Chorniy, *J. Pharm. Pharmacol.*, **51**, 264 (1999).
4. A.R. Saltiel and J.M. Olefsky, *Diabetes*, **45**, 1661 (1996).
5. S. Schwartz, P. Raskin, V. Fonseca and J.F. Graveline, *N. Engl. J. Med.*, **338**, 861 (1998).
6. J. Buse, B. Gumbiner, N.P. Mathias, D.M. Nelson, B.W. Faja, R.W. Whitcomb, The Troglitazone Insulin Study Group, *Diabetes Care*, **21**, 1455 (1998).
7. D. Quilliot, E. Walters, J.-P. Bonte, J.-C. Fruchart, P. Duriez and O. Ziegler, *Am. J. Clin. Nutr.*, **81**, 1117 (2005).
8. B.S. Furniss, A.J. Hannaford, P.W.G. Smith and A.R. Tetchell, *Vogels Text Book of Practical Organic Chemistry*, Longman Ltd., England, edn. 5, pp. 243-244, 1150 (1998).
9. R.M. Ambika Srivastava Singh, *Indian J. Chem.*, **44B**, 1868 (2005).
10. Y. Li, Z.S. Yang, H. Zhang, B.J. Cao, F.D. Wang, Y. Zhang, Y.-L. Shi, J.-D. Yang and B.-A. Wu, *Bioorg. Med. Chem.*, **11**, 4363 (2003).
11. W. Brand Willams, M.E. Cuvelier and C. Berset, *Lebensm.-Wissen. Technol.*, **28**, 25 (1995).
12. J.C. Espin, C. Soler Rivas and H.J. Wichers, *J. Agric. Food Chem.*, **48**, 648 (2000).
13. OECD, Guidelines No. 423 for the Testing of Chemicals Revised Draft Guideline 423 Acute Oral Toxicity, Paris (2000).
14. S.V. Kadnur and R.K. Goyal, *Indian J. Pharm. Sci.*, **67**, 453 (2005).
15. T.S. Frode and Y.S. Medeiros, *J. Ethnopharmacol.*, **115**, 173 (2008).
16. N. Rifaci, P.S. Bachorik and J.J. Albers, in eds.: In C.A. Burtis and E.R. Ashwood, *Lipid, Lipoprotein and Apolipoprotein*, Tretz Text Book of Clinical Chemistry, WB Saunder Company, Philadelphia, edn. 3, pp. 809-861 (1999).
17. R.P. MacDonald, *Standard Methods of Clinical Chemistry*, Academic Press, New York, pp. 215-222 (1953).
18. L. Thomas, *Clinical Laboratory Dragnostics*, TH Book Verlagsesellschaft, Frankfurt, pp. 208-214, 366-374 (1998).
19. N.W. Tretz, *Text Book of Clinical Chemistry*, WB Saumder Company, Philadelphia, edn. 3, p. 579 (1986).
20. M. Burstein, H.R. Scholnick and R. Morfin, *J. Lipid Res.*, **11**, 583 (1970).
21. M. Imran, B. Ilyas and S.A.K. Deepanjali, *J. Sci. Ind. Res.*, (India), **66**, 99 (2007).